Given the low number and apparent randomness of missing assessments (Little's MCAR 2 = 13.97, p = 0.12), mixed effects regression was used to generate estimates of treatment effects on anxiety from month 3 to 9 and t test to assess the differential change in anxiety between groups (group ! time interaction). Analyses were performed using SAS statistical software (version 9.2; SAS Institute Inc., Cary, N.C., USA).
Similar to depression, anxiety is common after acute coronary syndromes (ACS), and is an independent predictor of worse outcomes [1] [2] [3] . Yet, post-ACS psychological interventions have focused on treating depression. We previously reported that an enhanced depression care intervention involving patient preference for problem-solving therapy (PST), antidepressant medications, or both followed by stepped care according to treatment response was effective at reducing depressive symptoms after ACS with an effect size of 0.59 SD [4] . We report here the independent effect of this intervention on anxiety.
The trial design is described elsewhere [5] . Briefly, hospitalized ACS patients who were persistently depressed (Beck Depression Inventory, BDI [6] , score 6 10 within 1 week of hospitalization and again 3 months later) were recruited from 5 US hospitals between 2005 and 2008 and randomized to enhanced depression care or to usual care on a 1: 1 basis. Exclusion criteria were alcohol or drug dependency, dementia, psychosis or bipolar disorder, terminal illness, unavailability for follow-up, BDI score of 6 45, or suicidality. The institutional review boards at all institutions approved the protocol, and all participants provided written informed consent.
Enhanced depression care consisted of patient preference for brief problem-focused psychotherapy (i.e., PST) and/or pharmacotherapy and stepped care in which symptom severity was reviewed every 8 weeks and treatment was augmented according to predetermined decision rules. Usual care was defined by the patient's treating physician(s).
Anxiety and depressive symptoms were assessed within 1 week of hospitalization, and at 3, 5, 7, and 9 months. Anxiety was measured using the 7-item anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) [7] . Depressive symptoms were assessed by the BDI [6] . Outcome assessors were blinded to group assignment.
The secondary nature of the current analyses and sample selection (for depression vs. anxiety) limit interpretations that can be made, as does the use of HADS-A as a measure of anxiety in place of a diagnostic psychiatric interview. While an elevated HADS-A score has been associated with clinical diagnoses, anxiety disorders are heterogeneous and individual disorders may confer differing risks on post-ACS prognosis [14] . Nevertheless, elevated anxiety symptoms have been associated with a worse cardiac prognosis in prior studies [1] . Another limitation is that the comparison group was usual care rather than placebo/active control. Thus, we did not account for nonspecific effects of treatment on anxiety. Finally, 12 of the 80 patients randomized to treatment never received the intervention; this highlights the importance of considering the availability and acceptability of psychological interventions in post-ACS patients.
In conclusion, future interventions to reduce psychological distress after ACS should assess their effectiveness on both depression and anxiety symptoms. Those interventions with pleiotropic effects on both anxiety and depression may be best suited to not only improve quality of life in ACS survivors, but potentially, to reduce the risk of psychological distress on adverse cardiovascular outcomes. Future trials should consider whether to target depressed patients, alone, or to broaden enrollment criteria to include patients with depression and/or anxiety after ACS [15] . Although the intervention reduced anxiety symptoms compared to usual care, 42% of intervention participants had persistently elevated anxiety symptoms (HADS-A 1 7) at 9 months. Accordingly, post-ACS patients with combined anxiety and depressive symptoms may benefit from a sequential approach in which anxiety symptoms are monitored alongside depressive symptoms, and are targeted by alternating treatment strategies (psychotherapy and pharmacotherapy), depending on the individual history, course, and severity of the patients' symptoms and symptom profiles [16] .
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